Prospective Validation of an EHR-based Pancreatic Cancer Risk Model

Status Active, not recruiting

Clinical Trial Summary

The goal of this prospective observational cohort study is to validate a previously developed pancreatic cancer risk prediction algorith (the PRISM model) using electronic health records from the general population. The main questions it aims to answer are: - Will a pancreatic cancer risk model, developed on routine EHR data, reliably and accurately predict pancreatic cancer in real-time? - What is the average time from model deployment and risk prediction, to the date of pancreatic cancer development and what is the stage of pancreatic cancer at diagnosis? The risk model will be deployed on data from individuals eligible for the study. Each individual will be assigned a risk score and tracked over time to assess the model's discriminatory performance and calibration.

Clinical Trial Description

To prospectively validate, implement in real-time, and assess performance of an EHR- based PDAC risk-prediction model. To test the hypothesis that our model will reliably predict PDAC in a real-time clinical setting, we will conduct a multi-center prospective cohort study, deploying the PDAC risk model within the TriNetX federated network database, and will take the following steps: i) generate a risk prediction score for each individual under the care of 44 health care organizations (HCOs) in the USA ii) follow all individuals for up to 3 years to assess the primary end-point of PDAC development. The following metrics will be used to test the discriminative performance and calibration of the EHR-based PDAC risk model in predicting incident PDAC, at the end of the 3-year period: 1. AUROC, sensitivity, specificity, PPV/NPV for assessing discrimination 2. Calibration: for assessing the accuracy of estimates, based on the estimated to observed number of events ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05973331
Study type	Observational
Source	Beth Israel Deaconess Medical Center
Contact
Status	Active, not recruiting
Phase
Start date	July 17, 2023
Completion date	September 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05305001` - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Completed	`NCT01959672` - Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer	Phase 2
Recruiting	`NCT03673423` - Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
Terminated	`NCT02495896` - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05351983` - Patient-derived Organoids Drug Screen in Pancreatic Cancer	N/A
Completed	`NCT03054987` - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction	N/A
Terminated	`NCT02345460` - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study	Phase 2
Recruiting	`NCT02072616` - Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.	Phase 3
Completed	`NCT02174887` - Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer	Phase 1
Recruiting	`NCT03703063` - Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer	Phase 1
Terminated	`NCT04077372` - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers	N/A
Recruiting	`NCT03073785` - Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer	Phase 2
Completed	`NCT03665441` - Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC	Phase 3
Recruiting	`NCT04627246` - Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer	Phase 1
Not yet recruiting	`NCT06217666` - Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)	Phase 1
Recruiting	`NCT05585320` - A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT04119362` - PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
Completed	`NCT03105921` - Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma	N/A
Not yet recruiting	`NCT05287347` - Panc CA Risk Model & Biomarker Testing In High-Risk Cohort